von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts-Reference-Cited by-同舟云学术

von Willebrand factor activity levels are influenced by driver mutation status in polycythemia vera and essential thrombocythemia patients with well‐controlled platelet counts

Published:2022-09-28 Issue:6 Volume:109 Page:779-786
ISSN:0902-4441
Container-title:European Journal of Haematology
language:en
Short-container-title:European J of Haematology

Author:

Iizuka Kazuhide¹²³⁴^ORCID,Morishita Soji⁵⁶,Nishizaki Yuji⁷,Iizuka Yoshikazu³,Iriyama Noriyoshi³,Ochiai Tomonori²^ORCID,Yanagisawa Naotake⁷,Yasuda Hajime²^ORCID,Ando Jun²⁸,Gotoh Akihiko⁹,Takei Masami³,Hatta Yoshihiro³,Nakamura Hideki³,Nakayama Tomohiro¹,Komatsu Norio²⁵⁶¹⁰^ORCID

Affiliation:

1. Division of Laboratory Medicine, Department of Pathology and Microbiology Nihon University School of Medicine Tokyo Japan

2. Department of Hematology Juntendo University School of Medicine Tokyo Japan

3. Division of Hematology and Rheumatology, Department of Medicine Nihon University School of Medicine Tokyo Japan

4. Internal Medicine Atami Tokoro Memorial Hospital Shizuoka Japan

5. Laboratory for the Development of Therapies against MPN Juntendo University Graduate School of Medicine Tokyo Japan

6. Department of Advanced Hematology Juntendo University Graduate School of Medicine Tokyo Japan

7. Medical Technology Innovation Center Juntendo University Tokyo Japan

8. Department of Cell Therapy and Transfusion Medicine Juntendo University Graduate School of Medicine Tokyo Japan

9. Department of Hematology Tokyo Medical University Tokyo Japan

10. Pharmaessentia Japan KK Tokyo Japan

Publisher

Wiley

Subject

Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ejh.13866

Reference34 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

2. Propensity for hemorrhage and thrombosis in chronic myeloproliferative disorders

3. How I treat essential thrombocythemia

4. Cardiovascular Events and Intensity of Treatment in Polycythemia Vera

5. How I treat polycythemia vera